Strategic Asset Sales Paragon recently closed the sale of Emalex Biosciences to Teva, signaling readiness to monetize portfolio assets and potentially seek co-development or acquisition opportunities for remaining ventures and technologies.

Portfolio Financing With a total funding of around $185M and ongoing interest in building and funding life science companies, Paragon may seek partnerships or debt/funding arrangements to accelerate new portfolio company launches or scale existing ventures.

CNS Focus Paragon has a historically active role in CNS disorders through Emalex, presenting a channel for opportunities in neurology, movement disorders, and related therapies via collaboration, licensing, or co-development.

Strategic Partnerships Given Paragon’s model of creating, investing in, and building companies, there is potential for strategic partnerships in early-stage Biotech, AI-enabled drug discovery, and translational science to expand pipeline productivity.

International Reach As a global life science leader with Chicago roots and notable exits, Paragon could be open to cross-border licensing, joint ventures, or regional development deals to leverage global market access and portfolio synergies.